U.S. Medical Advisory Board

John E. Niederhuber, MD

Dr. John Niederhuber is a nationally renowned surgeon and researcher with a clinical emphasis on gastrointestinal, hepatobiliary and breast cancers. He is recognized for his pioneering work in hepatic artery infusion chemotherapy. Dr. Niederhuber has been a long-time external advisor to the National Cancer Institute and has authored and coauthored more than 180 publications and edited four books.

Dr. Niederhuber recently joined Inova Health System as Executive Vice President and CEO of the Inova Translational Medical Institute. Prior to that, he served as Director of the National Cancer Institute, one of the National Institutes of Health from 2006 until July, 2010. During his tenure as NCI director, Dr. Niederhuber shaped the Nation’s investment in cancer to address areas that are likely to pay the largest health dividends. He began The Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging have benefited under his direction. Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. He daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business and non-profit communities dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.